Quick Answer
EVO ICL works exceptionally well for nearsightedness (myopia). The FDA CIRCA clinical trial demonstrated that 99.4% of patients achieved 20/40 or better uncorrected vision and 94.2% achieved 20/20 or better. EVO ICL is FDA-approved for myopia from -3.00D to -20.00D and is particularly superior to laser alternatives at higher prescription levels (above -8D to -10D), where it delivers better optical quality with lower complication risk.
Detailed Explanation
Myopia (nearsightedness) is the world’s most common refractive error, affecting approximately 30% of the global population and projected to affect 50% by 2050. It causes distant objects to appear blurred because the eye focuses light in front of the retina rather than directly on it. EVO ICL addresses this by adding positive vergence power inside the eye, shifting the focal point backward to land precisely on the retina.
How EVO ICL corrects myopia — optical mechanics:
The EVO ICL is a biconcave lens (thinner at the center, thicker at the edges) that diverges incoming light before it passes through the natural crystalline lens. This divergence reduces the eye’s total optical power, compensating for the excessive focusing that causes myopia.
The specific power of each EVO ICL is calculated based on:
- The patient’s full refraction (sphere, cylinder, axis)
- Anterior chamber depth
- Keratometry (corneal curvature measurements)
- Target refraction (usually plano — correcting fully to zero residual error)
This custom calculation means each lens is specific to the individual eye.
Performance across the myopia spectrum:
EVO ICL does not perform uniformly across all prescription levels — it excels specifically where other procedures start to struggle:
Low myopia (-3D to -6D):
At this range, EVO ICL, LASIK, and PRK all achieve excellent outcomes. The procedural choice in this range is driven by other factors: corneal thickness, dry eye status, cost, and reversibility preference. LASIK is typically the most cost-effective option in this range for patients without contraindications.
Moderate myopia (-6D to -10D):
EVO ICL and LASIK both perform well, though EVO ICL begins to demonstrate advantages in optical quality — particularly contrast sensitivity and night vision — as the prescription rises. LASIK at -8D to -10D requires significant corneal ablation that can induce higher-order aberrations in some patients.
High myopia (-10D to -20D):
This is where EVO ICL is the clear clinical preference. LASIK outcomes above -10D are less predictable, require more corneal tissue removal, and produce more optical aberrations. At -15D or -20D, LASIK is either not feasible (insufficient corneal tissue) or produces suboptimal visual quality. EVO ICL corrects these prescriptions with the same procedure and technique used for -5D cases — the optical design scales effectively across the entire range.
Published studies comparing EVO ICL and LASIK in high myopia consistently show EVO ICL achieving superior uncorrected acuity, better contrast sensitivity, and higher patient satisfaction in the -10D to -20D range.
For recognized surgeons with specific expertise in high-myopia EVO ICL correction, see the EVO ICL Awards page.
Comparison with contact lens correction:
Contact lens correction for high myopia requires thick, heavy lenses with significant edge aberrations. Soft contact lenses struggle to maintain stable positioning in very high prescriptions. The visual quality of EVO ICL correction — centrally placed optics, constant position within the eye, no surface interaction — consistently produces better optical performance than contact lens correction at equivalent prescriptions.
Many patients with -12D to -20D prescriptions who have worn thick glasses their entire lives describe EVO ICL as transformative not just for convenience but for visual quality improvement.
Stability of myopia correction over time:
EVO ICL does not prevent myopia from progressing after surgery. The lens corrects the refractive error that exists at the time of surgery. If myopia continues to progress post-operatively, the correction becomes insufficient over time.
For this reason, prescription stability is a required prerequisite for surgery. Patients whose myopia is still actively advancing are not candidates. Most surgeons require less than 0.5D of change in the 12 months prior to surgery.
In patients with stable myopia at the time of surgery, long-term refractive stability with EVO ICL is excellent. Studies following patients for 10 to 15 years show minimal refractive drift attributable to the lens itself.
Night vision and optical quality:
One of the most consistently praised aspects of EVO ICL by patients with high myopia is night vision quality. Thick glasses and high-prescription contacts produce edge distortion, reduced peripheral clarity, and — for high prescriptions especially — compromised night vision. EVO ICL eliminates these aberrations. The optic sits centered in the visual axis without the peripheral distortion of spectacle correction.
Halos and glare in low-light conditions are the primary optical side effect of EVO ICL (see What Are the Risks of EVO ICL Surgery?) but for high myopes who transition from thick glasses or contacts to EVO ICL, the net night vision experience is almost always described as dramatically improved.
Important Considerations
The correction range of -3D to -20D represents the FDA-approved bounds. Prescriptions below -3D are not well-suited to EVO ICL because the risk-benefit profile of intraocular surgery is not justified for small corrections where LASIK or PRK are effective and simpler.
The -20D upper bound is not a ceiling in all international markets (some surgeons in Europe and Asia treat higher prescriptions off-label), but within the United States, this is the regulatory limit and the extent of the evidence base reviewed by the FDA.
Patients with myopia who also have significant astigmatism should ask specifically about the Toric EVO ICL, which corrects both components simultaneously. See Can EVO ICL Correct Astigmatism? for details.
What to Do Next
If you have moderate to high myopia and have been told LASIK is not appropriate for your prescription or corneal anatomy, EVO ICL is worth a formal evaluation. Request anterior chamber depth measurement at your consultation — this is the key anatomical factor for candidacy.
Review Is EVO ICL Better Than LASIK? to understand exactly where EVO ICL’s advantages over laser correction are most pronounced for myopia patients.
Related Questions
Can EVO ICL also fix my astigmatism? Yes — see Can EVO ICL Correct Astigmatism? for how the toric lens design addresses cylinder correction.
How long will my correction last? Read How Long Does EVO ICL Last? for the long-term refractive stability picture.
What if my prescription changes after surgery? See What Happens If My Vision Changes After EVO ICL? for options when post-surgical progression occurs.